Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
In development
Reference number: GID-TA10935
Expected publication date: TBC
Please note that, following discussion between NICE and the company, this appraisal will be rescheduled to align with NICE’s proportional approach to technology appraisals. The timelines for this appraisal are to be confirmed.